Immutep Limited Faces Securities Fraud Class Action Lawsuit: Investors' Legal Options
Immutep Limited Faces Securities Fraud Class Action Lawsuit
The Schall Law Firm, a prominent player in shareholder rights litigation, has brought attention to a class action lawsuit involving Immutep Limited, a biopharmaceutical company listed on NASDAQ under the ticker IMMP. Investors who acquired shares during a specific time frame are now urged to consider joining the legal action aimed at addressing alleged securities fraud by the company.
Background of the Case
The lawsuit focuses on violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, accompanied by Rule 10b-5, as enforced by the U.S. Securities and Exchange Commission. The relevant class period for this lawsuit extends from March 24, 2025, to March 12, 2026.
During this timeframe, the company's statements regarding its clinical trial results—particularly for its drug eftilagimod alfa—are in question. Immutep communicated to its investors that the TACTI-004 trial was showing
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.